Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600418 | 0.84 | ERN1 (0.50) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL7598088 | 0.84 | ERN1 (0.50) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL2850824 | 0.80 | ERN1 (0.45) | ALDH1A1ERN1MAPTLMNA | |
| SCHEMBL16581610 | 0.79 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL16581598 | 0.79 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL16581589 | 0.77 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL2852251 | 0.76 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL31269571 | 0.73 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1LPAR3LPAR2HTT | |
| SCHEMBL3956860 | 0.72 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 | |
| SCHEMBL6851438 | 0.72 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1LPAR3LPAR2ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204038-A1 | Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid | CARLONI SILVIA | 2010-08-12 | — | — | US | disclosed |
| EP-1765496-B1 | CATALYSTS BASED ON COPPER COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID | ENDURA SPA (IT) | 2010-07-14 | — | — | EP | disclosed |
| US-7723539-B2 | Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid | ENDURA S.P.A. (IT) | 2010-05-25 | — | — | US | disclosed |
| US-20080021237-A1 | Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid | ENDURA S.P.A. (IT) | 2008-01-24 | — | — | US | disclosed |
| EP-1765496-A1 | CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID | ENDURA S.p.A. (IT) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123254-A1 | CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID | ENDURA S.P.A. (IT) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021237-A1 | Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid | SCO2, ME1, ME3 | ALDH1A1 1925/4885L3MBTL1 4716/4885LPAR3 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.